Novo CEO concedes R&D setbacks as CagriSema data stay mixed
The cagrilintide-semaglutide combination has repeatedly landed below investor expectations, keeping pressure on Novo's obesity pipeline.
MH
By Maren Holt · Senior Reporter, GLP-1
Aug 5 03:00 ETSource: Fierce Biotech
The wire
- 01Novo Nordisk's chief executive acknowledged a 'couple of setbacks' in research and development as the amylin-plus-semaglutide combination CagriSema posted further mixed results, Fierce Biotech reports.
- 02CagriSema is Novo's main answer to Lilly's tirzepatide and retatrutide, so its trajectory shapes what prescribers and payers will have available next.
- 03Detailed endpoint data and regulatory timing were not laid out in the report; how the mixed readouts affect filings remains open.
From the source
Read at fiercebiotech.comNovo CEO accepts ‘couple of setbacks’ in R&D as CagriSema posts more mixed data